Honasa Consumer Ltd's acquisition of a majority stake in Fluence Pharma marks a strategic pivot toward health-beauty convergence, as India's beauty and personal care (BPC) brands increasingly seek clinical credibility and prescription-led growth. For overseas buyers and distributors, this signals a rising demand for science-backed, inside-out beauty solutions that combine topical products with nutraceuticals, opening new sourcing and partnership opportunities in the Indian market.
## Deal details
Honasa, parent of Mamaearth, will acquire a 58% stake in Mumbai-based Fluence Pharma at an enterprise value of approximately ₹135 crore, with the remaining stake to be purchased in phases over 5-7 years. Fluence sells condition-specific OTC supplement kits for hair and skin care through a network of over 3,000 dermatologists, using patented Cyclical Nutrition Therapy. The company generated about ₹40 crore in revenue in FY26 with an EBITDA margin above 20%.
## Market signal
Industry executives say the deal reflects a wider shift in both India and global markets, where beauty, wellness, and healthcare are increasingly blurring. Honasa estimates India's vitamins, minerals, and supplements market at over ₹16,000 crore, with online searches for hair and skin nutraceuticals rising around 40% between FY24 and FY26. This trend is reshaping dealmaking, as seen in Marico's acquisition of Plix in 2023 and HUL's stake in Oziva.
## What buyers should watch
For overseas importers and distributors, Honasa's move highlights growing consumer demand for integrated regimes combining topical products with ingestible supplements for concerns like hair fall and acne. The company plans to leverage Fluence's patented science and doctor testimonials while using its own digital distribution capabilities. This creates potential opportunities for suppliers of nutraceutical ingredients, packaging, and contract manufacturing for science-led beauty-health products.
## Regulatory and channel signals
Because these products sit in the OTC space, they lend themselves well to modern trade, e-commerce, and quick commerce channels. Companies with strong consumer distribution networks may have an advantage in scaling them. The deal also signals increasing regulatory and clinical credibility requirements, as brands seek to build trust through evidence-led approaches.
## Sourcing context
Honasa's existing portfolio includes science-led skincare brands like The Derma Co. and Dr Sheth's, which have popularized active ingredients such as salicylic acid, niacinamide, and hyaluronic acid among Indian consumers. The company's entry into nutraceuticals through Honasa Health, a wholly-owned subsidiary, indicates a long-term commitment to building a consumer nutraceutical franchise, potentially creating sustained demand for related raw materials and packaging solutions.